Nonalcoholic Fatty Liver Disease (NAFLD)

Donna R. Cryer, JD, CEO of the Global Liver Institute and Wayne Eskridge, Founder, and CEO of the Fatty Liver Foundation, discuss nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)

Donna R. Cryer, JD, has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as president and chief executive officer of the Global Liver Institute, the innovation and collaboration platform for the liver community. For almost a decade Mrs. Cryer led CryerHealth, a healthcare consulting firm she founded, providing strategic counsel to top biopharmaceutical companies, patient advocacy organizations, and emerging technology firms on patient engagement in health information technology, drug discovery, and clinical decision making. She is a frequent speaker on the topic of patient-centeredness and patient engagement in healthcare transformation.

Wayne Eskridge was first diagnosed with liver disease in 2010 and, as a result of his own experiences, he became aware of an acute need for an educational resource from a patient perspective. At the core of his motivation is the fact that an estimated 100 million Americans already have fatty liver disease and are unaware of it. While there is currently no medical treatment for NAFLD/NASH, lifestyle changes can be effective. Prevention through education is the only practical solution today. His desire to help others avoid his experiences led him to the decision to become a patient advocate and to create the Fatty Liver Foundation.